127 related articles for article (PubMed ID: 12576917)
21. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
[TBL] [Abstract][Full Text] [Related]
22. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
24. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Depierre A
Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
[TBL] [Abstract][Full Text] [Related]
28. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
29. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
30. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
Smyth JF; Coleman RE; Nicolson M; Gallmeier WM; Leonard RC; Cornbleet MA; Allan SG; Upadhyaya BK; Bruntsch U
BMJ; 1991 Dec; 303(6815):1423-6. PubMed ID: 1837743
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
32. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
33. Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy.
Jantunen IT; Flander MK; Heikkinen MI; Kuoppala TA; Teerenhovi L; Kataja VV
Acta Oncol; 1993; 32(4):413-5. PubMed ID: 8369129
[TBL] [Abstract][Full Text] [Related]
34. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
[TBL] [Abstract][Full Text] [Related]
35. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
Park JO; Rha SY; Yoo NC; Kim JH; Roh JK; Min JS; Kim BS; Chung HC
Am J Clin Oncol; 1997 Dec; 20(6):569-72. PubMed ID: 9391542
[TBL] [Abstract][Full Text] [Related]
36. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
[TBL] [Abstract][Full Text] [Related]
37. Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone.
Liaw CC; Wang CH; Chang HK; Kao CY; Huang JS
Chang Gung Med J; 2000 Jul; 23(7):413-9. PubMed ID: 10974756
[TBL] [Abstract][Full Text] [Related]
38. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
Roila F
Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
[TBL] [Abstract][Full Text] [Related]
39. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
40. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
Dick GS; Meller ST; Pinkerton CR
Arch Dis Child; 1995 Sep; 73(3):243-5. PubMed ID: 7492164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]